老虎證券

BUZZ-Soleno gains as US FDA approves its drug to treat rare genetic disorder

Reuters
03-27
BUZZ-Soleno gains as US FDA approves its drug to treat rare genetic disorder

** Shares of Soleno Therapeutics SLNO.O rise 33.98% to $65.61 premarket

** Late on Wednesday, U.S. FDA approved co's drug to treat a rare genetic disorder, making it first treatment available for patients who experience feelings of intense and persistent hunger

** The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder that is caused by an error in one or more genes

** The drug will have an annual average cost of $466,200 and will be dosed as per patients' weight and will be available from April

** Up to last close, stock up ~9% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10